27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Benefits and risks of statins relative to neurological outcomes should be considered when prescribed for at-risk NDD populations. 3 key findings →
Design: cohort study Participants: 288,515 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with CKD could have an elevated dementia risk. 4 key findings →
Design: cohort study Participants: 37,049 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Recent research has revealed an association between hearing impairment and dementia. 4 key findings →
Design: longitudinal study Participants: 154,783 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. 2 key findings →
Design: longitudinal study Participants: 100,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The same daily ACB score was associated with a different degree of risk, depending on the ACB ratings of the individual drugs comprising the score. 5 key findings →
Design: cohort study Participants: 10,698 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Study objective To examine the risks and compare the occurrences of major long-term side effects (sexual dysfunction, bone fractures, diabetes, cardiovascular morbidity, acute myocardial infarction [MI], and dementia) in patients with prostate cancer who received androgen-deprivation therapy (ADT) with those who did not. 5 key findings →
Design: cohort study Participants: 201,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We identified a non-linear association of type 2 diabetes duration and the risk of dementia. 1 key finding →
Design: cohort study Participants: 13,761 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings demonstrate the importance of community-based patient-centered care strategies for stroke survivors that address their range of health needs and prevent more costly acute care use. 2 key findings →
Design: cohort study Participants: 29,673 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Therefore, we conducted a longitudinal study to examine whether PM2.5 affects the episodic memory decline, and also explored the potential mediating role of increased neuroanatomic risk of Alzheimer's disease associated with exposure. 5 key findings →
Design: longitudinal study Participants: 998 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The incidence of MCR is high in older adults. 2 key findings →
Design: cohort study Participants: 3,128 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our prediction model was internally evaluated based on five-fold cross-validation on discrimination and calibration, and it was further compared with existing prediction scales. 2 key findings →
Design: longitudinal study Participants: 2,416 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results encourage an independent validation cohort study to confirm the indication that the plasma Aβ 1-40 /Aβ 1-42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design. 2 key findings →
Design: cohort study Participants: 276 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Compared with PWOH, PWH were at 58% higher risk for dementia despite HIV treatment with ART. 2 key findings →
Design: cohort study Participants: 5,381 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Incident use of neuroleptics in Ontario nursing homes is substantial. 3 key findings →
Design: cohort study Participants: 19,780 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Adults with TSCI are at a heightened risk for ADRD. 2 key findings →
Design: cohort study Participants: 7,019 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This cohort study found that COVID-19 mortality decreased over time during 2020 and that patient demographic characteristics and comorbidities were associated with higher clinical severity. 5 key findings →
Design: cohort study Participants: 174 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Data collected from clinical trials and cohort studies, such as dementia studies, are often high-dimensional, censored, heterogeneous and contain missing information, presenting challenges to traditional statistical analysis. 1 key finding →
Design: cohort study Participants: 1,037 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results support an association between the use of ADT in the treatment of prostate cancer and an increased risk of Alzheimer's disease in a general population cohort. 4 key findings →
Design: retrospective cohort Participants: 16,888 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 9,455 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among older Medicare beneficiaries with heart failure, there is a higher overall burden of comorbidity and greater prevalence of discordant comorbidity among the oldest old. 5 key findings →
Design: cohort study Participants: 201,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dialysis modality is associated with incident dementia in a cohort of older ESRD patients. 4 key findings →
Design: cohort study Participants: 121,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes. 2 key findings →
Design: cohort study Participants: 6,401 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia is among various diseases affecting the elderly, who is also at a high risk for fractures. 3 key findings →
Design: cohort study Participants: 66,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →